5 October 2009

Contents

Conference reports

• 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention, 19-23 July 2009, Cape Town

• First results of new integrase compound: GSK1349572

• Raltegravir in treatment-naive patients

• Nevirapine vs atazanavir/ritonavir in treatment-naive patients: ARTEN study

• Darunavir/r monotherapy studies

• Maraviroc results similar to efavirenz when analysed using more sensitive tropism test

• Lipid and metabolic changes with ARV combinations

• Maximal suppression achieved with three drugs: no additional virological impact of raltegravir intensification

• Tenofovir and renal safety

• Time from seroconversion to treatment in Europe and Africa

• Pharmacokinetics of atazanavir/ritonavir during pregnancy

• Presentation with late stage HIV in women diagnosed during pregnancy

• Low transmission rates and favourable pregnancy outcomes reported in the DREAM study

• Pregnancy rates and outcomes among women in the DART trial

• Pregnancy outcomes in HAART exposed infants in Johannesburg

• Efavirenz conceptions in Soweto

• Impact of regimen and duration of therapy on risk of mother-to-child HIV transmission in Johannesburg

• A cost-effectiveness analysis of the OCTANE trial

• The PEARL study

• Results from HSV-2 acyclovir studies

• Overview of TB-related studies at IAS

Antiretrovirals

• CD4 responses after viral suppression for more than 7 years on HAART

• Raltegravir approved in Europe for treatment-naive patients

• 50mg and 100mg ritonavir doses achieve similar levels of saquinavir in Thai patients